Insight Molecular Diagnostics (iMDx) announced a favorable Medicare policy expanding reimbursement for donor-derived cell-free DNA (dd-cfDNA) testing, supporting its GraftAssure transplant monitoring assays. The updated policy increases allowable testing frequency for kidney and heart transplant patients, enhancing patient access and encouraging in-house testing at transplant centers. This aligns with iMDx's strategy to commercialize faster, local testing kits pending FDA approval. The policy also cites iMDx research, reinforcing its leadership in transplant diagnostics.
Traini, a Silicon Valley AI company specializing in pet emotional intelligence, has partnered with TECNO to integrate its pet emotion translation technology natively into TECNO smartphones. This allows users to understand their pets' emotions and nee...
Law Offices of Howard G. Smith announced class action lawsuits against Futu Holdings, Hub Group, Insulet Corporation, and Photronics for allegedly making false or misleading statements during specific periods. The lawsuits claim these companies misre...
Ahead of its August 18, 2026 earnings report, Home Depot has seen mixed investor activity. A public official sold between $15,001 and $50,000 worth of stock, while Copeland Capital Management drastically reduced its stake by 94.6%. Conversely, Adviso...
Danaher Corporation reported stronger-than-expected Q2 2026 earnings and revenue, driven by its Life Sciences segment, with EPS of $1.94 and revenue of $6.27 billion beating estimates. However, the stock fell nearly 12% in premarket trading due to in...
Hancock Whitney Corporation is set to report its Q2 earnings on July 21, 2026, with analysts expecting an EPS of $1.55 and revenue near $399 million. The bank recently gained regulatory approval to acquire One Florida Bank, a strategic move expected ...
